BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy

Vasiliki Panou; Amber Louw; Weronika Maria Szejniuk; Christos Meristoudis; Siaw Ming Chai; Louise Lynggård Andersen; Azadeh Birbaneh Asghari; Mogens Vyberg; Johnni Hansen; Jenette Creaney; Oluf Dimitri Røe

doi:10.1183/13993003.congress-2020.4490

BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy

Vasiliki Panou, Amber Louw, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Louise Lynggård Andersen, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe

European Respiratory Journal 2020 56: 4490; DOI: 10.1183/13993003.congress-2020.4490

Vasiliki Panou

1Department of Respiratory Medicine, Odense University Hospital & Department of Respiratory Diseases, Aalborg University Hospital, Odense & Aalborg, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: vasiliki_panou@hotmail.com

Amber Louw

2PathWest Laboratory Medicine, QEII Medical Centre & Edith Cowan University, Perth, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Weronika Maria Szejniuk

3Department of Oncology, Aalborg, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christos Meristoudis

4Institute of Pathology, Aalborg, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Siaw Ming Chai

5Division of Anatomical Pathology, QEII Medical Centre PathWest Laboratory Medicine , Perth, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Louise Lynggård Andersen

4Institute of Pathology, Aalborg, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Azadeh Birbaneh Asghari

4Institute of Pathology, Aalborg, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mogens Vyberg

6Aalborg University, Aalborg, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Johnni Hansen

7Danish Cancer Society, Copenhagen, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jenette Creaney

8National Centre for Asbestos Related Disease, Centre for Respiratory Health, University of Western Australia & Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Oluf Dimitri Røe

9Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health Trust & Department of Clinical and Molecular Medicine, Levanger & Trondheim, Norway

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics

Figures

Tables

Download figure
Open in new tab
Download powerpoint

Tables

Figures

Pemetrexed group
N=77 BSC group
N=91 P-value
BAP1- N=58 N=44 <0.01
Male N=68 N=74 0.29
Epithelioid subtype N=48 N=50 0.75
Age (years,median,IQR) 71(12) 75(15) 0.06
PS:0,1 N=68 N=50 <0.01

Vol 56 Issue suppl 64 Table of Contents

Table of Contents
Index by author

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy

Message Subject (Your Name) has sent you a message from European Respiratory Society

Message Body (Your Name) thought you would like to see the European Respiratory Society web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy

European Respiratory Journal Sep 2020, 56 (suppl 64) 4490; DOI: 10.1183/13993003.congress-2020.4490

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy

European Respiratory Journal Sep 2020, 56 (suppl 64) 4490; DOI: 10.1183/13993003.congress-2020.4490

Share This Article:

Main menu

User menu

Search

BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy

Figures

Tables

Citation Manager Formats

More in this TOC Section

Related Articles

Contact us

	Pemetrexed group N=77	BSC group N=91	P-value
BAP1-	N=58	N=44	<0.01
Male	N=68	N=74	0.29
Epithelioid subtype	N=48	N=50	0.75
Age (years,median,IQR)	71(12)	75(15)	0.06
PS:0,1	N=68	N=50	<0.01

Main menu

User menu

Search

BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy

Figures

Tables

Citation Manager Formats

Jump To

More in this TOC Section

Related Articles

Contact us